# OnCo record hair-antiandrogens-alopecia (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/hair-antiandrogens-alopecia/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "hair-antiandrogens-alopecia" ;
  schema:name "Antiandrogens for hair: spironolactone, finasteride, dutasteride"@en ;
  schema:description "Because hair thinning on endocrine therapy follows the pattern of androgenetic alopecia, the drugs used for that pattern are sometimes added. The evidence in cancer survivors cannot separate them from minoxidil, the one guideline that addresses spironolactone says not to use it routinely, and an expert panel advised against finasteride and dutasteride in breast cancer."@en ;
  schema:url <https://onco.cc/technologies/hair-antiandrogens-alopecia/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Antiandrogen> ;
  schema:citation <https://doi.org/10.1016/j.annonc.2020.11.005>, <https://doi.org/10.1111/jdv.70021>, <https://doi.org/10.1007/s10549-018-4996-3>, <https://doi.org/10.1001/jamadermatol.2018.5071> ;
  onco:status "emerging" ;
  onco:tag "complementary", "supportive-care", "hair-loss", "evidence:insufficient" ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/exemestane/> ;
  onco:terms <https://onco.cc/terms/alopecia-endocrine-therapy/>, <https://onco.cc/terms/alopecia-persistent-chemotherapy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/> .